After PTAB ruled against Teva (TEVA) on two patents, RBC Capital analyst Randall Stanickly says he's not surprised by the decision. He thinks the impact of the ruling on Mylan (MYL) will probably be low given its lack of an approved generic Copaxone and its focus on its EPIPEN p.r. difficulties. He notes that PTAB is supposed to issue a decision on the remaining Teva patent by September 1, while a DC trial on Copaxone is set to start on September 26. The analyst keeps a $71 price target and Outperform rating on Teva.

Teva Pharmaceuticals announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology AAN Annual Meeting. "90% of HD patients experience chorea,3,4 so it's important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience," said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. "We remain committed to exploring ways to evolve the AUSTEDO treatment experience to meet the needs of the HD community, and these latest real-world data reinforce the role of the 4-week Titration Kit for AUSTEDO in empowering patients with HD chorea to find their optimal dose, adhere consistently to their treatment plan, and achieve effective outcomes."